Keros Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Revenue	214.71	3.55	0.15	-	20.1	-	Upgrade
Revenue Growth (YoY)	91657.69%	2250.99%	-	-	-	-	Upgrade
Cost of Revenue	10.45	-	-	-	55.14	33.86	Upgrade
Gross Profit	204.26	3.55	0.15	-	-35.04	-33.86	Upgrade
Selling, General & Admin	40.94	40.75	34.83	27.53	21.33	12.8	Upgrade
Research & Development	173.63	173.63	135.26	87.27	-	-	Upgrade
Operating Expenses	214.57	214.38	170.09	114.79	21.33	12.8	Upgrade
Operating Income	-10.31	-210.83	-169.94	-114.79	-56.37	-46.66	Upgrade
Interest Expense	-	-	-	-0	-0	-0.01	Upgrade
Interest & Investment Income	24.48	23.5	14.76	3.64	0.03	-	Upgrade
Currency Exchange Gain (Loss)	-0.86	-0.95	-0.21	-0.61	-	-	Upgrade
Other Non Operating Income (Expenses)	1.24	1.24	2.4	7.08	-0.38	1.13	Upgrade
Pretax Income	14.56	-187.05	-152.99	-104.68	-56.73	-45.53	Upgrade
Income Tax Expense	10.34	0.3	-	-	2.01	-0.17	Upgrade
Net Income	4.21	-187.35	-152.99	-104.68	-58.74	-45.36	Upgrade
Net Income to Common	4.21	-187.35	-152.99	-104.68	-58.74	-45.36	Upgrade
Shares Outstanding (Basic)	39	37	29	25	23	16	Upgrade
Shares Outstanding (Diluted)	39	37	29	25	23	16	Upgrade
Shares Change (YoY)	23.97%	27.13%	16.66%	8.17%	50.48%	566.41%	Upgrade
EPS (Basic)	0.11	-5.00	-5.20	-4.15	-2.52	-2.93	Upgrade
EPS (Diluted)	0.11	-5.00	-5.20	-4.15	-2.52	-2.93	Upgrade
Free Cash Flow	43.31	-162.8	-126.97	-71.3	-63.17	-37.19	Upgrade
Free Cash Flow Per Share	1.12	-4.35	-4.31	-2.83	-2.71	-2.40	Upgrade
Gross Margin	95.13%	100.00%	100.00%	-	-174.34%	-	Upgrade
Operating Margin	-4.80%	-5938.96%	-112543.71%	-	-280.46%	-	Upgrade
Profit Margin	1.96%	-5277.55%	-101319.21%	-	-292.26%	-	Upgrade
Free Cash Flow Margin	20.17%	-4585.91%	-84087.42%	-	-314.29%	-	Upgrade
EBITDA	-9.01	-209.6	-169.13	-114.12	-56	-46.38	Upgrade
EBITDA Margin	-4.20%	-	-	-	-278.58%	-	Upgrade
D&A For EBITDA	1.3	1.23	0.82	0.67	0.38	0.28	Upgrade
EBIT	-10.31	-210.83	-169.94	-114.79	-56.37	-46.66	Upgrade
EBIT Margin	-4.80%	-	-	-	-280.46%	-	Upgrade
Revenue as Reported	214.71	3.55	0.15	-	20.1	-	Upgrade

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q